StockNews.AISignal intelligenceMAZE
Browse public MAZE signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Maze Therapeutics' stock has dropped sharply by 31.17% despite positive clinical trial results for MZE829, which showed significant reductions in urinary albumin-to-creatinine ratios. The firm plans to advance its pivotal program, further supported by a robust cash balance and favorable analyst ratings.
View signal analysisMAZE reports Phase 1 results for MZE782 targeting key health disorders. MZE782 shows significant increases in amino acid excretion, confirming efficacy. MZE782 well tolerated; no serious adverse events reported during trials. Company plans Phase 2 trials for MZE782 efficacy in PKU and CKD. MAZE shares up over 52% and reach new 52-week high.
View signal analysisMaze Therapeutics valued at $690.37 million after Nasdaq debut. Stock rose nearly 1% on first trading day.
View signal analysisMaze Therapeutics raised $140 million in an IPO for kidney disease drugs. This sets the potential for a significant first biotech listing in 2023.
View signal analysisMaze Therapeutics plans for a $728.1 million IPO valuation in the U.S.
View signal analysis